Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 483-491

  Thibault, Alain ^a,d,e   Samid, Dvorit ^a,e   Tompkins, Anne C ^a   Figg, William D ^a   Cooper, Michael R ^a,e   Hohl, Raymond J ^c   Trepel, Jane ^a   Liang, Bertrand ^a   Patronas, Nicholas ^b   Venzon, David J ^a   Reed, Eddie ^a   Myers, Charles E ^a,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DRUG METABOLITE; MEVALONIC ACID; MEVINOLIN; UBIQUINONE;

ADULT; AGED; ARTICLE; CANCER; CANCER PATIENT; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; FATIGUE; FEMALE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; MYOPATHY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIDDLE AGED; NEOPLASMS; UBIQUINONE;

EID: 0030010318     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Fumagalli, R., Grossi, E., Paoletti, P., and Paoletti, R. Studies on lipids in brain tumors. 1. Occurrence and significance of sterol precursors of cholesterol in human brain tumors. J. Neurochem., 11: 561-565, 1964.
2. Maltese, W. A. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase in human brain tumors. Neurology, 33: 1294-1299, 1983.
3. Goldstein, J. L , and Brown, M. S. Regulation of the mevalonate pathway. Nature (Lond.), 343: 425-430, 1990.
4. Maltese, W. A., Refendini, R., Green, R. A., Sheridan, K. M., and Donley, D. K. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Clin. Invest., 76: 1748-1754, 1985.
5. Prasanna, P., Thibault, A., Liu, L., and Samid, D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and phenylacetate against glioma cells. J. Neurochem., 66: 710-716, 1996.
6. Littman, M. L., Taguchi, T., and Mosbach, E. H. Effect of cholesterol-free, fat-free diet and hypocholestrolemic agents on growth of transplantable animal tumors. Cancer Chem. Rep. 50, 25-45, 1966.
7. Shack, S., Prasanna, P., Hudgins, W. R., and Samid, D. Experimental therapies for malignant gliomas: targeting the mevalonate pathway of cholesterol synthesis. Proc. Am. Assoc. Cancer Res., 55, 409, 1994.
8. Brown, M. D., and Goldstein, J. L. The hyperlipoproteinemias and other disorders of lipid metabolism. In: J. D. Wilson (ed.), Harrison's Principles of Internal Medicine, 12th ed., pp. 1814-1825. New York: McGraw,-Hill, 1991.
9. Kornbrust, D J., MacDonald, J. S., Chennekatu, P. P., Duchai, D. M., Stubbs, R. J , Germerhausen, J. I., and Alberts, A. W. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J. Pharmacol. Exp. Ther., 248: 498-505, 1989.
10. Folkers, K., Langsjoen, P., Willis, R., Richardson, P., Xia, L. J., Ye, Q. C., and Tamagawa, H. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA, 87: 8931-8934, 1990.
11. Chariot, P., Abadia, R., Agnus, D., Dana, C., and Charpentier, C. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med., 94: 109-110, 1993.
12. Abe, K., Ishibashi, K., Ohmae, M., Kawabe, K., and Katsui, G Determination of ubiquinone in serum and liver by high-speed liquid chromtography. J. Nutr. Sci. Vitaminol., 24, 555-567, 1978.
13. Alberts, A W., Chen, J., Kuron, G., Hunt, V., Huff, J , Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., Patchett, A., Monahan, R., Currie, S., Stapley, E., Albers-Shonberg, G., Hensens, O., Hirshfield, J., Hoogsteen, K., Liesch, J., and Springer, J. Mevinolin a highly potent competitive inhibitor of hydroxy methylglutaryl coenzyme A reductase and a cholesterol-lowering agent. Proc. Nat. Acad. Sci. USA, 77: 3957-3961, 1980.
14. Brown, M. D., and Goldstein, J L. Drugs used in the treatment of hyperlipoproteinemias. In: A. G. Gilman (ed.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, pp. 874-897. New York: Pergamon Press, 1990.
15. Hoogstraten, B. Reporting treatment results in solid tumours. In: M. E. Buyse (ed.), Cancer clinical trials, pp. 139-156. Oxford: Oxford Medical Publications, 1990.
16. Schmidt, J. D., Scott, W. W., Gibbons, R., Johnson, D. E., Prout, G. R., Loening, S., Soloway, M., deKernion, J., Pontes, J. E., Slack, N. E., and Murphy, G. P. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer (Phila.), 45: 1937-1946, 1980.
17. Thibault, A., Sartor, A. O., Cooper, M R., Figg, W. D., and Myers, C. E. A 75% decline in prostate specific antigen (PSA) predicts survival in hormone refractory prostate cancer. Proc. Am. Assoc. Cancer Res., 34: 192, 1993.
18. Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V., Schwartz, M., and Fossa, S. D. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 11: 607-615, 1993.
19. Hollander, M., and Wolfe, D. A. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973.
20. Armitage, P. Test for linear trend in proportions and frequencies. Biometrics, 11: 375-386, 1955.
21. Alberts, A. W., MacDonald, J. S., Till, A. E., and Tobert, J. A. Lovastatin. Cardiovasc. Drug Rev., 7: 89-109, 1989.
22. Stein, E. A., Till, A E., Dobrinska, M. R., Gregg, M. H., Entwistle, L A., Hessey, J. Lovastatin multiple-dose pharmacokinetics. Pharm. Res., 5 (Suppl.): S-150, 1988.
23. Dobrinska, M. R., Stubbs, R. J., and Gregg, M. H Effects of dose and food on HMG-CoA reductase inhibitor profiles after lovastatin (MEVACOR). Pharmacol. Res., 5 (Suppl.): S-182, 1988.
24. 14C-lovastatin in chronic renal failure. Clin. Pharmacol. Ther., 50, 437-441, 1991.
25. Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Ponpliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (Washington DC), 260: 1934-1937, 1993.
26. Vogt, A., Qian, Y., Blaskovich, M. A., Fossum, R. D , Halmiton, A. D., and Sebti, S. M A non-peptide mimetic of ras-CAAX: selective inhibition of farnesyltransferase and ras processing. J. Biol. Chem., 270: 660-664, 1995
27. Sepp-Lorenzino, L., Oliff, A., Gibbs, J. B., Kohl, N. E., Ma, Z., Lebwhol, D E., and Rosen, N. Farnesyl:protein transferase inhibitors block the anchorage dependent and -independent growth of human tumor cell lines. Proc. Am. Assoc Cancer Res., 36: 431, 1995.